Psoriatic Arthritis

Bimekizumab treatment for psoriatic arthritis demonstrated rapid, clinically meaningful improvements to patient reported outcomes that were sustained up to 1 year, according to data published in Rheumatology.

Difficult-to-treat psoriatic arthritis was common in a large, real-life cohort, with key risk factors including extensive psoriasis, higher BMI and a history of inflammatory bowel disease, according to data published in Rheumatology.

Serious infections were uncommon among patients with psoriatic arthritis exposed to targeted therapies for the first time in “a large and exhaustive” French cohort, according to data published in RMD Open.

CLEVELAND — Dermatology and rheumatology often work together in the treatment of psoriasis and psoriatic arthritis.

Healio has compiled May’s most-read news in dermatology.

The FDA has expanded the indication of Rinvoq to include active, polyarticular juvenile idiopathic arthritis and psoriatic arthritis in children aged 2 years and older, according to an AbbVie press release.

Patients with rheumatic diseases demonstrate a high reliance on opioids around the time of diagnosis, and significant numbers of patients were not on appropriate treatment in the year afterward, according to data in Clinical Rheumatology.

CLEVELAND — With myriad treatment options now available for psoriasis vulgaris, recent research is focusing on reaching higher goals, Anthony P. Fernandez, MD, PhD, said at the Medical Dermatology Therapy Update III meeting.

Low stress resilience in men may be linked to an increased risk for developing psoriasis or psoriatic arthritis, according to a study.

Although TNF inhibitors remain the first choice biologic for many rheumatologists treating psoriatic arthritis, interleukin-17 inhibitors may soon overtake them, according to a market analysis from Spherix Global Insights.